| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Tomentosin targets multiple molecular pathways. It suppresses the production of inflammatory mediators in RAW264.7 cells by inhibiting NF-κB activation. It also induces telomere shortening and caspase-dependent apoptosis in cancer cells. Additionally, it operates through mechanisms including NF-κB pathway modulation and induction of endoplasmic reticulum (ER) stress.
|
|---|---|
| ln Vitro |
In vitro, Tomentosin suppresses the production of inflammatory mediators in RAW264.7 cells by inhibiting NF-κB activation. It induces telomere shortening and caspase-dependent apoptosis in cervical cancer cells. It also causes apoptosis and inhibits proliferation, migration, and invasion of pancreatic cancer cells.
|
| ln Vivo |
In vivo, Tomentosin has demonstrated anti-inflammatory and anticancer activities in preclinical models. Its ability to inhibit NF-κB and induce apoptosis suggests potential for treating inflammatory diseases and cancer.
|
| Enzyme Assay |
The activity of Tomentosin is assessed using cell-based assays. Its anti-inflammatory effect is measured by its ability to suppress the production of inflammatory mediators such as NO, TNF-α, and IL-6 in activated macrophages. Its anticancer activity is evaluated by its effects on cancer cell proliferation, migration, invasion, and apoptosis.
|
| Cell Assay |
Cellular assays for Tomentosin involve treating RAW264.7 macrophages to study its anti-inflammatory effects and various cancer cell lines (e.g., pancreatic, cervical) to study its anticancer effects. Cell viability, inflammatory marker production, and apoptotic markers are assessed.
|
| Animal Protocol |
In vivo studies are conducted in animal models of inflammation (e.g., carrageenan-induced paw edema) and cancer (e.g., xenograft models). The compound is administered via intraperitoneal (i.p.) injection or oral gavage.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Tomentosin are not extensively detailed in publicly available sources. As a natural product, it is typically formulated in DMSO for in vitro studies.
|
| Toxicity/Toxicokinetics |
Tomentosin is intended for research use only and is not approved for clinical use. Its toxicological profile would be evaluated in preclinical studies.
|
| References | |
| Additional Infomation |
Tomentosin is a sesquiterpene lactone. It has been reported to exist in Carpesium macrocephalum, Inula japonica, and other organisms with relevant data.
Tomentosin is a natural sesquiterpene lactone with dual anti-inflammatory and anticancer activities. It is a valuable tool for studying NF-κB signaling, inflammation, and cancer cell apoptosis. |
| Molecular Formula |
C15H20O3
|
|---|---|
| Molecular Weight |
248.32
|
| Exact Mass |
248.141
|
| CAS # |
33649-15-9
|
| PubChem CID |
155173
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
416.2±45.0 °C at 760 mmHg
|
| Flash Point |
185.1±28.8 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.511
|
| LogP |
2.12
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@H]1C[C@@H]2[C@H](CC=C1CCC(=O)C)C(=C)C(=O)O2
|
| InChi Key |
AVFIYMSJDDGDBQ-CUOATXAZSA-N
|
| InChi Code |
InChI=1S/C15H20O3/c1-9-8-14-13(11(3)15(17)18-14)7-6-12(9)5-4-10(2)16/h6,9,13-14H,3-5,7-8H2,1-2H3/t9-,13+,14+/m0/s1
|
| Chemical Name |
(3aR,7S,8aR)-7-methyl-3-methylidene-6-(3-oxobutyl)-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0271 mL | 20.1353 mL | 40.2706 mL | |
| 5 mM | 0.8054 mL | 4.0271 mL | 8.0541 mL | |
| 10 mM | 0.4027 mL | 2.0135 mL | 4.0271 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
